Reviva Pharmaceuticals Holdings, Inc.
RVPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,131 | $3,725 | $4,114 | $4,681 |
| G&A Expenses | $1,898 | $2,348 | $2,425 | $1,604 |
| SG&A Expenses | $1,898 | $2,348 | $2,425 | $1,604 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,030 | $6,073 | $6,538 | $6,285 |
| Operating Income | -$4,030 | -$6,073 | -$6,538 | -$6,285 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $22 | $27 | $111 | $30 |
| Pre-Tax Income | -$4,008 | -$6,046 | -$6,428 | -$6,255 |
| Tax Expense | $3 | $8 | $5 | $5 |
| Net Income | -$4,011 | -$6,054 | -$6,433 | -$6,259 |
| % Margin | – | – | – | – |
| EPS | -0.055 | -0.12 | -0.13 | -0.16 |
| % Growth | 54% | 7.7% | 18.8% | – |
| EPS Diluted | -0.055 | -0.12 | -0.13 | -0.16 |
| Weighted Avg Shares Out | 72,686 | 49,848 | 48,644 | 33,147 |
| Weighted Avg Shares Out Dil | 72,686 | 49,848 | 48,644 | 33,147 |
| Supplemental Information | – | – | – | – |
| Interest Income | $59 | $23 | $86 | $47 |
| Interest Expense | $3 | $5 | $12 | $5 |
| Depreciation & Amortization | $4,030 | $6,073 | $6,538 | -$782 |
| EBITDA | -$4,005 | -$6,041 | -$6,416 | -$6,250 |
| % Margin | – | – | – | – |